[en] Tiotropium is a long-acting anticholinergic bronchodilator, inhaled only once a day, which produces relaxation of airway smooth muscle through antagonism of acetylcholine at M3-muscarinic receptors. Its duration of action is at least 24 h with once daily administration of tiotropium. Several studies have shown its efficacy and its good tolerance in the treatment of patients who are suffering from moderate to very severe chronic obstructive pulmonary disease (COPD). Tiotropium improves spirometric measurements and quality of life, and reduces dyspnea and exacerbation rate in COPD patients.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Corhay, Jean-Louis ; Université de Liège - ULiège > Pneumologie-Allergologie
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Language :
French
Title :
Le tiotropium: une nouvelle option therapeutique dans la bronchopneumopathie chronique obstructive
Alternative titles :
[en] Tiotropium: A New Therapeutic Option in Chronic Obstructive Pulmonary Disease
Lopez A.D, Murray CCJL. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-3.
Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003;97:115-22.
Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop report. Am J Respir Crit Care Med 2001;163:1256-76 (updated 2003: available at www.goldcopd. com.Accessed December 19, 2003).
O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
Disse B, Speck GA, Rominger KL, Witek Jr T, Hammer R. Tiotropium (Spiriva®): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64.
Disse B, Reichl R, Speck GA, Traunecker W, Rominger KL, Hammer R. Ba679 Br., a novel anticholinergic bronchodilatator. Life Sci 1993;52:537-44.
Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilatation with once-daily dosing of tiotropium (Spiriva®) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42.
Maessen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilatator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch study group. Eur respir J 1995;8:1506-13.
Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
Van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJG. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive disease. Eur Respir J 2002;19:639-44.
Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
Donohue JF, van Noord JA, Bateman ED, et al. A 6 month, Placebo-Controled Study Comparing Lung Fonction and Health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404.
van Noord JA, Aumann J, Janssens E, Mueller A, Cornelissen PJG. Comparison of once-daily tiotropium, twice daily formoterol and the free combination once-daily, in patients with COPD. Am J Respir Crit Med 2003;167:A320.
van Noord JA, Aumann J, Janssens E, Folgering H, Mueller A, Cornelissen PJG. Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatement periods. Am J Respir Crit Med 2003;167:A95.
Combivent inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either alone: An 85-day multicenter trial. Chest 1994;105:1411-9.
van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratriopium. Eur Respir J 2000;15:878-85.
O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-40.
Celli B, Wallack RZ, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-8.
Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek Jr ThJ. Effective delivery of particles with HandiHaler, dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. Journal of aerosol medicine 2001;14:309-15.
